Travere Therapeutics
TVTX
129 hedge funds and large institutions have $1.1B invested in Travere Therapeutics in 2018 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 46 increasing their positions, 46 reducing their positions, and 11 closing their positions.
628% more call options, than puts
Call options by funds: $9.96M | Put options by funds: $1.37M
91% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 11
21% more capital invested
Capital invested by funds: $908M → $1.1B (+$188M)
8% more funds holding
Funds holding: 119 → 129 (+10)
1.1% more ownership
Funds ownership: 102.26% → 103.36% (+1.1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 46
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
+$39.6M |
| 2 |
PNC Financial Services Group
Pittsburgh,
Pennsylvania
|
+$6.77M |
| 3 |
BlackRock
New York
|
+$6.65M |
| 4 |
State Street
Boston,
Massachusetts
|
+$5.06M |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$4.98M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$18.9M |
| 2 |
Point72 Asset Management
Stamford,
Connecticut
|
-$13.4M |
| 3 |
Millennium Management
New York
|
-$9M |
| 4 |
GTC
Ghost Tree Capital
New York
|
-$7.03M |
| 5 |
AC
Ascend Capital
Orinda,
California
|
-$5.83M |
TVTX Hedge Fund Activity: Q2 2018 in Review
129 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Travere Therapeutics (TVTX) for Q2 2018, worth a combined $1.1B — up 21% from $908M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new TVTX positions and 11 closed out — a net gain of 10 holders — while 46 added to existing stakes and 46 trimmed.
The largest buyer was Manulife (Manufacturers Life Insurance), adding an estimated $39.6M. The largest seller was Invesco, cutting an estimated $18.9M.
- 129 institutional investors held Travere Therapeutics (TVTX) as of Q2 2018, up from 119 in Q1 2018.
- Funds reported $1.1B of Travere Therapeutics stock for Q2 2018, up 21% quarter-over-quarter.
- 21 funds opened new Travere Therapeutics positions in Q2 2018 and 11 closed out, a net change of +10 holders.
- The largest Travere Therapeutics buyer in Q2 2018 was Manulife (Manufacturers Life Insurance), an estimated $39.6M added.
- The largest Travere Therapeutics seller in Q2 2018 was Invesco, an estimated $18.9M sold.
Based on aggregated 13F filings for Q2 2018.